Home The History of Synthetic Biology Designing Synthetic Biotics Pipeline Our People Leadership Board of Directors Founders and Advisors Investors + Media Company Overview News News Releases In the News Events & Presentations Events Presentations Publications Stock Information Stock Quote & Chart Analyst Coverage Corporate Governance Governance Highlights Management Team Board of Directors Committee Composition Board Diversity Matrix Financials Quarterly Results Investor Resources FAQs Contact IR Email Alerts RSS Feeds Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU) Read more about Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU) Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks Read more about Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks Synlogic Reports Second Quarter 2022 Financial Results and Provides Business Update Read more about Synlogic Reports Second Quarter 2022 Financial Results and Provides Business Update Synlogic Announces Second Quarter 2022 Conference Call and Webcast Read more about Synlogic Announces Second Quarter 2022 Conference Call and Webcast Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU) Read more about Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU) Synlogic Announces Appointment of General Counsel and Corporate Secretary Read more about Synlogic Announces Appointment of General Counsel and Corporate Secretary Synlogic to Present at the 2022 National PKU Alliance (NPKUA) Conference Read more about Synlogic to Present at the 2022 National PKU Alliance (NPKUA) Conference Synlogic to Present at the 2022 HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation Conference Read more about Synlogic to Present at the 2022 HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation Conference Synlogic Reminds Stockholders of 2022 Annual General Meeting Details Read more about Synlogic Reminds Stockholders of 2022 Annual General Meeting Details Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1618 for the Treatment of Phenylketonuria Read more about Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1618 for the Treatment of Phenylketonuria Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last » Subscribe to Investor Resources Contact IR Investor FAQs RSS Feeds Investor Email Alerts Email
Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU) Read more about Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU)
Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks Read more about Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks
Synlogic Reports Second Quarter 2022 Financial Results and Provides Business Update Read more about Synlogic Reports Second Quarter 2022 Financial Results and Provides Business Update
Synlogic Announces Second Quarter 2022 Conference Call and Webcast Read more about Synlogic Announces Second Quarter 2022 Conference Call and Webcast
Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU) Read more about Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU)
Synlogic Announces Appointment of General Counsel and Corporate Secretary Read more about Synlogic Announces Appointment of General Counsel and Corporate Secretary
Synlogic to Present at the 2022 National PKU Alliance (NPKUA) Conference Read more about Synlogic to Present at the 2022 National PKU Alliance (NPKUA) Conference
Synlogic to Present at the 2022 HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation Conference Read more about Synlogic to Present at the 2022 HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation Conference
Synlogic Reminds Stockholders of 2022 Annual General Meeting Details Read more about Synlogic Reminds Stockholders of 2022 Annual General Meeting Details
Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1618 for the Treatment of Phenylketonuria Read more about Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1618 for the Treatment of Phenylketonuria